The Age Blind Spot in Cancer Clinical Trials Is Moving Toward the Core of Treatment Decision-Making

Advances in cancer treatment often put new drugs, immunotherapy, and molecular targeted therapies in the spotlight. But in the clinic, many of the patients actually facing these choices are already older adults, while also carrying chronic diseases, medication burdens, and differences in physical function. In its latest profile of Enrique Soto Perez de Celis, Oncodaily focuses on an issue that is not flashy, but could change the quality of treatment: whether clinical trial evidence is sufficient to answer the real needs of older adults with cancer.

According to the headline and summary of that report, Soto Perez de Celis is concerned with the “evidence gap” in cancer clinical trials. This is not simply a demographic issue, but a clinical issue that extends into how physicians assess efficacy, safety, dose adjustments, quality of life, and whether patients can tolerate treatment side effects. If older adults are underrepresented in trials, study results may look statistically strong but still fail to fully reflect the patient profiles most commonly seen on the clinical front line.

Older adults with cancer are not a single uniform group. Among people who are all 80 years old, some can still live independently, while others are affected by frailty, cognitive changes, declining kidney function, or polypharmacy. Traditional clinical trials often use age, comorbidities, or functional status as enrollment thresholds. The original intent is to reduce risk and control variables, but this may also exclude the very group of people who most need answers. As a result, after drugs reach the market, medical teams are left to make judgments in a more complex real-world environment.

This gap is especially acute in oncology. Cancer itself intersects closely with aging, and the incidence of many cancer types rises with age. Yet the development pace of new therapies is often driven by data from participants who are better able to tolerate intensive follow-up and standard treatment regimens. When the evidence base skews toward younger and healthier patients, older adults may face two opposite risks: undertreatment because of concerns about side effects, or overtreatment based on data that are not fully applicable.

To narrow this gap, the key is not only to “add in” older patients. More practical directions include incorporating geriatric assessment, functional status, fall risk, cognition, and care support into trial design, while also including quality of life, treatment discontinuation, hospitalization, and the ability to manage daily self-care as endpoints with greater clinical meaning. These data may not be as intuitive as tumor shrinkage rates, but they are closer to the consequences that patients and families truly face every day.

Currently available information on the same event is quite limited. Apart from Oncodaily’s brief source, no external reports on the same event were found that could be used for cross-checking. Therefore, this article does not extend into speculation about Soto Perez de Celis’s specific arguments, institutional role, or quoted remarks in that piece. What can be confirmed is that the issue this report points to has become a structural challenge that global oncology care cannot avoid: longevity societies are changing the fundamental population of cancer treatment, and clinical evidence must keep up.

If clinical trials can more honestly reflect the differences among older patients, the beneficiaries will not be limited to older populations. It will also force cancer research to rethink what effective treatment means: not only extending survival under ideal conditions, but making treatment outcomes more closely match real life on the basis of being tolerable, sustainable, and respectful of patients’ goals.